HIV/AIDS Drug Resistance
Some HIV-1 HRI sequence variations affect sensitivity to T-20 but not T-1249 fusion inhibitors
Published in AIDS Weekly, December 5th, 2005
According to recent research from Germany, "Sequence variations in the gp41 heptad repeat 1 (HR1) region have been identified in some treatment-naive HIV-1-infected patients, but it remained elusive whether they confer resistance to fusion inhibitors."
"[Our objective was] to evaluate whether naturally occurring sequence variations in the HIV-1 group M gp41 HRI region affect the sensitivity to inhibition by T-20 and T-1249."
"Site-directed mutagenesis was used to generate HIV-1 NL4-3 mutants containing changes in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (2005-12-05)
More Articles from AIDS Weekly
- Behavioral Medicine
POZ parties are an emerging risk for HIV-infected men who have unprotected sex with men - HIV/AIDS Diagnostics
Rapid HIV tests more cost effective than ELISAs in low-risk populations - HIV/AIDS Diagnostics
Screening assay detects CD8+ cell noncytotoxic anti-HIV response - HIV/AIDS Transmission
CD8 cell presence in semen does not correlate with levels of HIV-1 RNA shedding - HIV/AIDS Transmission
Chorioamnionitis is associated with placental transmission of HIV-1 subtype E - Antifungals
Oral posaconazole has clinical activity against CNS fungal infections - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
